ONL Therapeutics featured on the OIS Retina Podcast
ANN ARBOR, MI – June 30, 2020
This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for Merck. This led to several executive positions and eventually to building and scaling private companies. His career came full circle when investors recruited him to ONL Therapeutics a year ago. In this episode, host Firas Rahhal, MD, digs into ONL’s portfolio of therapies in development, the latest on the company’s clinical trials, and how as a corporate leader Esposito draws on his military experience.
About ONL1204
ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company’s ONL1204 development program focused its first indication on the treatment of retinal detachment, a condition for which the compoun has been granted orphan drug designation by the United States Food and Drug Administration (FDA). Clinical trial plans are focused first on the acute indication of retinal detachment, with continuing preclinical work occurring to enable clinical trials in other disease indications, including glaucoma, age-related macular degeneration (AMD), and inherited retinal degeneration (IRD; also known as retinitis pigmentosa).
About ONL Therapeutics
ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a novel breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering an entirely new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD, and IRD.
For more information about ONL Therapeutics, please visit www.onltherapeutics.com.
Company Contact:
ONL Therapeutics, Inc.
Linda Kemnitz
lkemnitz@onltherapeutics.com